Prostate cancer
Conditions
Interventions
Gold Standard:All cases were verified by surgical resection, biopsy histopathological results or clinical follow-up data. Lesions that were difficult to obtain histopathology (such as bone metastasis,
2.After anti-tumor treatment, the imaging follow-up showed that the lesion volume was reduced or disappeared. The follow-up time was 3 to 15 months (median follow-up time was 7 months).
Index test:1. Main observation points:
Comparison of the number of lesions detected by the two examinations: Comparison of the number of lesions detected by 18F-PSMA PET/CT and 18F-PSMA PET/MR for pri
Sponsors
Yunnan cancer hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Patients with clinical suspicion of prostate cancer or recurrence of prostate cancer after treatment. 2.Patients without contraindications to PET/CT and PET/MR examinations. 3.Complete clinical pathological and imaging data. 4.Signed informed consent to accept 18F-PSMA-1007 PET/CT and PET/MR examinations.
Exclusion criteria
Exclusion criteria: 1.Patients who cannot tolerate the test or have contraindications to the test. 2.Patients with other primary malignant tumors. 3.Patients with other diseases that cause lymphadenopathy. 4.Patients who do not accept biopsy and regular follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mMaximum standardized uptake value(SUVmax);Number of lesions;Pathological or follow-up results;Prostate Specific Antigen(PSA); | — |
Countries
China
Contacts
Public ContactLong Chen
Yunnan cancer hospital
Outcome results
None listed